TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20008943
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitor (SSRI) or venlafaxine, with or without cognitive-behavioral therapy (CBT)
Study: 10818263
Drug: NPY (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPY (both doses)
Study: 8815021
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic prophylaxis (Group B, n = 50)
Study: 1836894
Drug: Fluoxetine 40
Normalized name: fluoxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 40 mg
Study: 6441721
Drug: Vasoactive intestinal
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive intestinal polypeptide (VIP) infusion in controls
Study: 6441721
Drug: Vasoactive intestinal
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive intestinal polypeptide (VIP) infusion in hyperprolactinaemics
Study: 29122965
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of dairy protein supplementation
Study: 24240607
Drug: Rifaximin, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin, administered in cycles of 7-10 days per month over a period of 3 months
Study: 22321770
Drug: Fidaxomicin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fidaxomicin (200 mg every 12 h for 10 days)
Study: 22321770
Drug: Vancomycin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (125 mg every 6 h for 10 days)
Study: 27281556
Drug: Letrozole monotherapy
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole monotherapy
Study: 21335417
Drug: Tamoxifen monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen monotherapy
Study: 15693603
Drug: Mandibular overdenture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular overdenture on two implants (IMP-group)
Study: 10347961
Drug: Inhalatory corticosteroids
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalatory corticosteroids therapy with educational program (EDUCASMA)
Study: 8562152
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with LV (200 mg/m2) plus 5‐FU (350 mg/m2), both given i.v. (days 1‐4) and i.p. (days 1 and 3) every 4 weeks for a total of six courses
Study: 8971294
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg hydrocortisone
Study: 11500348
Drug: Albuterol (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (n = 28)
Study: 16333385
Drug: Conventional three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional three dose scheme (month 0, 1, 6)
Study: 16333385
Drug: Two dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two dose brief scheme (month 0, 1)
Study: 16333385
Drug: Three dose
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three dose brief scheme (month 0, 1, 2)
Study: 12882862
Drug: Preprandial insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preprandial insulin aspart (immediately before meal start)
Study: 12882862
Drug: Postprandial insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postprandial insulin aspart (immediately after a meal or a maximum of 30 min after meal start)
Study: 1377307
Drug: Slow-release verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release verapamil (240 mg once daily)
Study: 3160356
Drug: Nitrendipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (20 mg once daily)
Study: 20484610
Drug: Gastric-retentive extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric-retentive extended-release formulation of gabapentin
Study: 20484610
Drug: Gastric-retentive extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric-retentive extended-release formulation of gabapentin with food
Study: 20484610
Drug: Immediate-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release formulation of gabapentin
Study: 11012558
Drug: S 17092
Approvals — FDA: no, EMA: no, PMDA: no
Description: S 17092 800 mg
Study: 11012558
Drug: S 17092
Approvals — FDA: no, EMA: no, PMDA: no
Description: S 17092 1200 mg
Study: 11012558
Drug: S 17092
Approvals — FDA: no, EMA: no, PMDA: no
Description: S 17092 (all doses)
Study: 8881815
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg budesonide
Study: 10950051
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg budesonide
Study: 1384078
Drug: i.v. opiate
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. opiate by un-signalled infusion
Study: 25659440
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) administration
Study: 8669327
Drug: Complete hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Complete hormone blockade (CHB)
Study: 8669327
Drug: Monotherapy (orchidectomy)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (orchidectomy)
Study: 29857497
Drug: HP diet
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP diet with ≥4 weekly servings of lean beef (B)
Study: 26417901
Drug: Sublingual liquid
Normalized name: B Complex with B-12 Sublingual Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual liquid birch pollen preparation (SB) 3333 AUN/ml
Study: 20500832
Drug: Fluvastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 80 mg
Study: 9511827
Drug: Antibody response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Antibody response against teichoic acid
Study: 9511827
Drug: Positive antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive antibody response to at least one of the three antigens
Study: 30696435
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies
Study: 24667662
Drug: Three-day regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-day regimen of dihydroartemisinin-piperaquine (total dose 360 mg dihydroartemisinin and 2880 mg piperaquine)
Study: 20636866
Drug: Topical agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical agents (specific agents not mentioned)
Study: 16900483
Drug: All-trans-retinoic acid
Normalized name: all-trans-Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans-retinoic acid (ATRA) at 90 mg/m2/day in three divided doses for 3 consecutive days per week, combined with interferon-α2a (IFN-α2a) at 3 × 106 U/m2/day subcutaneously for 5 consecutive days per week in 4 week cycles.
Study: 8842905
Drug: Patient controlled
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient controlled analgesia with morphine (0.015 mg/kg)
Study: 23433769
Drug: AZD9668 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9668 60 mg twice daily for 4 weeks
Study: 21334098
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg of daily oral dexamethasone for 2 days
Study: 21334098
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of daily oral prednisone for 5 days
Study: 10468681
Drug: Orange juice
Normalized name: Orange juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange juice (200 mL, 75 mg of 13C-urea)
Study: 10468681
Drug: Citric acid
Normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citric acid solution (200 mL, 50 mg of 13C-sodium acetate)
Study: 25548849
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of botulinum toxin A (BoNT A) after ablative fractional CO2 laser treatment
Study: 16706244
Drug: Metronidazole 1%
Normalized name: METRONIDAZOLE 1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 1% gel (once-daily application)
Study: 18560640
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride gel
Study: 17885577
Drug: Clozapine treatment
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine treatment
Study: 30130627
Drug: Alfuzosin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin (10 mg extended release)
Study: 30130627
Drug: Alfuzosin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin (2.5 mg immediate release)
Study: 26004888
Drug: Standard-dose selenium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose selenium supplementation (Se-, n = 75) in SIRS patients
Study: 21529740
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg 12 hours before intervention with another 40 mg preprocedure dose)
Study: 6366100
Drug: O-(beta-hydroxyethyl)-rutosides (HR)
Normalized name: Padimate O
DrugBank: Padimate O (DB11570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: O-(beta-hydroxyethyl)-rutosides (HR) 2 g/day
Study: 28325013
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy combined with Electrical Stimulation (ES)
Study: 20211180
Drug: Prolonged low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prolonged low-dose peginterferon-alpha2a therapy and beta-blockers
Study: 10520842
Drug: Intravenous hyoscyamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hyoscyamine (0.25 mg)
Study: 25428627
Drug: 5% lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine patches
Study: 28701501
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure treatment (systolic BP <140 mm Hg)
Study: 28430722
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine and bupivacaine injection
Study: 31887803
Drug: Control (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (normal saline injection)
Study: 26010427
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of peginterferon α-2b plus low and escalating doses of ribavirin (group 1)
Study: 10715306
Drug: Capecitabine 1,331
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine 1,331 mg/m²/d bid continuously (arm A)
Study: 9928755
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 20 mg once daily
Study: 1304283
Drug: Iopanoic acid
Normalized name: Iopanoic Acid
DrugBank: Iopanoic acid (DB08946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iopanoic acid (500 mg orally twice a day for the first 3 weeks) and carbimazole (30 mg orally in three divided doses)
Study: 25500574
Drug: Intramuscular midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular midazolam (0.3 mg/kg)
Study: 25047312
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (0.15 mg/kg)
Study: 12583944
Drug: Intermittent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent chemotherapy (break in chemotherapy, re-starting on the same drug on progression)
Study: 12583944
Drug: Continuous chemotherapy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous chemotherapy (until progression)
Study: 10224577
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin by infusion (group II, n = 12)
Study: 1899455
Drug: Average dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average dialysis treatment duration of less than 3.5 hours
Study: 1899455
Drug: Average dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average dialysis treatment duration longer than 3.5 hours
Study: 29415906
Drug: NKCP® (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKCP® (250 mg daily for 4 weeks)
Study: 27112031
Drug: Percutaneous radio-frequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous radio-frequency ablation with ethanol injection (2.5-9.6 mL) and temperature control at 45-56 °C for more than 10 min.
Study: 27112031
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (ablation without ethanol injection, lesions more than 5 mm from gastrointestinal tract).
Study: 7479215
Drug: Non-dialysis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-dialysis treatment
Study: 19743725
Drug: 3-step acne
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-step acne system (salicylic acid cleanser 2% twice daily, salicylic acid toner 2% once daily, solubilized BPO gel 5% twice daily)
Study: 19743725
Drug: Control (cleanser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (cleanser twice daily plus clindamycin 1%-BPO 5% gel twice daily)
Study: 11042828
Drug: hCG injection
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG injection followed by oocyte retrieval at 34 hours (group A)
Study: 3912695
Drug: Adriamycin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adriamycin (40 mg/m2) and cyclophosphamide (500 mg/m2)
Study: 3912695
Drug: Adriamycin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adriamycin (40 mg/m2) and cisplatin (50 mg/m2)
Study: 31117967
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin regimen (30-40 mg/m2 on days 1, 8, 15, 22, 29, 36, and 43)
Study: 31117967
Drug: Triweekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triweekly cisplatin regimen (80-100 mg/m2 on days 1, 22, and 43)
Study: 31117967
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin regimen
Study: 26435363
Drug: Conventional photodynamic
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional photodynamic therapy (c‐PDT)
Study: 22648722
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (EPA and DHA 600 mg in a 2:1 ratio)
Study: 16142802
Drug: conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional treatment without GP IIb/IIIa inhibitor (group 2, 70 patients)
Study: 17207299
Drug: Gabapentin 400
Normalized name: gabapentin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 400 mg 6 hourly for 7 days plus continuous wound infusion of ropivacaine 0.75% for 30 h
Study: 17207299
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules identical to those of gabapentin for 7 days and continuous wound infusion of normal saline for 30 h
Study: 17207299
Drug: Gabapentin and
Normalized name: Gabapentin and mecobalamin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin and ropivacaine treatment
Study: 2894911
Drug: propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol 80 mg X 2
Study: 25592254
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (AQ‐AS, DHA‐PQ, AL, MQAS)
Study: 21533301
Drug: Glycyrrhetinic acid-containing
Normalized name: Glycyrrhetinic acid-containing product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyrrhetinic acid-containing barrier repair cream (BRC-Gly, Atopiclair®)
Study: 21533301
Drug: Ceramide-dominant barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceramide-dominant barrier repair cream (BRC-Cer, EpiCeram®)
Study: 10146979
Drug: Clentiazem (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clentiazem (calcium channel blocker)
Study: 18341664
Drug: Topical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical placebo ointment
Study: 2934438
Drug: Topical betamethasone
Normalized name: betamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betamethasone ointment
Study: 22030947
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg caffeine (C)
Study: 22030947
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg caffeine + 50 mg geranamine (C + G 50 mg)
Study: 22030947
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg caffeine + 75 mg geranamine (C + G 75 mg)
Study: 18465339
Drug: Nine courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nine courses of three-weekly cyclophosphamide, methotrexate and 5-fluorouracil (CMF)
Study: 11756615
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g acetaminophen daily (n = 20)
Study: 3551577
Drug: Copovithane schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copovithane schedule B: 10 g/m2 i.v. over 30 min once a week until progression, unacceptable toxicity, or up to 18 months
Study: 18515521
Drug: Sinecatechins ointment
Normalized name: sinecatechins Topical Ointment
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sinecatechins ointment 10%
Study: 26719035
Drug: Regular concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular concurrent exercise training for 30 weeks
Study: 19460078
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of different pacing sites and AF suppression pacing
Study: 11157369
Drug: High dialysate
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dialysate calcium concentration (HDCa; 3.5 mEq/L)
Study: 28383533
Drug: One capsule
Normalized name: GABAdone Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule of daily iron supplement (34 mg of ferrous sulfate)
Study: 28383533
Drug: Two capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two capsules of daily iron supplement (34 mg of ferrous sulfate)
Study: 26488676
Drug: Low-dose mirtazapine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose mirtazapine
Study: 21362764
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 200 mg subcutaneously every 2 weeks for 52 weeks
Study: 9690695
Drug: ziprasidone 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: ziprasidone 160 mg/day
Study: 9690695
Drug: haloperidol 15
Normalized name: haloperidol 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: haloperidol 15 mg/day
Study: 9690695
Drug: ziprasidone 4
Normalized name: ziprasidone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ziprasidone 4 mg/day
Study: 9690695
Drug: ziprasidone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ziprasidone 10 mg/day
Study: 9690695
Drug: ziprasidone 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: ziprasidone 160 mg/day and haloperidol 15 mg/day
Study: 2568105
Drug: Beta 2
Normalized name: Beta 2 globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta 2 sympathomimetic drugs administered by aerosol inhaler
Study: 29514693
Drug: Standard induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard induction therapy (non-MSC treatment)
Study: 17138156
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion at 50 ng/kg per minute under sedation with propofol (4 mg/kg per hour)
Study: 17138156
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion at 50 ng/kg per minute under sedation with midazolam (0.2 mg/kg per hour)
Study: 8776195
Drug: Experimental design
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental design approach using a combination of solution concentration, air exchange rate, and body type in a cross-classified design for estimating historical exposures to formaldehyde.
Study: 25661470
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment only
Study: 18380741
Drug: Control (antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (antibiotics and analgesics alone)
Study: 18380741
Drug: Sitz bath
Normalized name: SITZ BATH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitz bath (twice-daily) along with antibiotics and analgesics
Study: 20082586
Drug: Nateglinide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (120 mg)
Study: 15477634
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg once daily
Study: 3629205
Drug: Soft-laser therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft-laser therapy (He-Ne laser, 6 J/cm2, 9 treatments)
Study: 23893828
Drug: Usual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual therapy alone
Study: 25632085
Drug: Fingolimod (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod (mean exposure to study drug, 2.4 years)
Study: 21396848
Drug: Lidocaine-ketorolac gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine-ketorolac gel (5 g 2.5% lidocaine + 0.3% ketorolac tromethamine) 1 hour before TPB
Study: 16238896
Drug: IV paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV paracetamol 1 g
Study: 15053490
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy for 20 minutes twice per week over the course of one month